Article Sidebar

PDF
Issue: Vol. 51 No. 8 (2026): JOURNAL OF MILITARY PHARMACO-MEDICINE No.8 - 2026
Section: Articles
DOI: 10.56535/jmpm.v51i8.2086
Date Published: 28/08/2026
Views 28
Downloads 8
How to Cite
Dinh, T. L. A., Le, T. Y., & Nguyen, H. A. (2026). TREATMENT OUTCOMES OF FIRST-LINE OSIMERTINIB IN ELDERLY PATIENTS WITH ADVANCED EGFR-MUTANT NON-SMALL CELL LUNG CANCER. Journal of Military Pharmaco-medicine, 51(8), 189-198. https://doi.org/10.56535/jmpm.v51i8.2086

TREATMENT OUTCOMES OF FIRST-LINE OSIMERTINIB IN ELDERLY PATIENTS WITH ADVANCED EGFR-MUTANT NON-SMALL CELL LUNG CANCER

Thi Lan Anh Dinh1, Thi Yen Le1,2,3, , Hoang Anh Nguyen2
1 Vietnam National Cancer Hospital
2 Hanoi Medical University
3 Viet Nam University of Traditional Medicine

Main Article Content

Abstract

Objectives: To evaluate the efficacy and safety of first-line osimertinib in elderly patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC). Methods: This retrospective-prospective descriptive study included 51 patients aged ≥ 65 years with stage IIIC-IV NSCLC harboring EGFR mutations, treated with first-line osimertinib at K Hospital from May 2019 to May 2025. Results: The objective response rate (ORR) was 82.4%, and the disease control rate (DCR) was 96.1%. Among patients with brain metastases, ORR was 76.2%, and DCR was 100%. Median progression-free survival (PFS) and overall survival (OS) were 26.7 and 46.8 months, respectively. The 3-year survival rates were 45.4% for PFS and 76.9% for OS. No independent prognostic factors for OS were identified in multivariable analysis. Adverse events were mainly grade 1 - 2, with no grade 3 - 4 toxicities observed; one case of grade 1 interstitial lung disease was reported. Conclusion: First-line osimertinib demonstrated high efficacy and good tolerability in elderly patients with EGFR-mutant advanced NSCLC.

Keywords

Osimertinib, Elderly patients, Lung cancer, EGFR mutation

Article Details

References

1. Hardavella G, Frille A, Chalela R, et al. How will lung cancer screening and lung nodule management change the diagnostic and surgical lung cancer landscape? Eur Respir Rev. 2024; 33(172):230232. DOI: 10.1183/16000617.0232-2023.
2. Marur S, Singh H, Mishra-Kalyani P, et al. FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. Semin Oncol. 2018; 45(4):220-225. DOI: 10.1053/ j.seminoncol.2018.08.007.
3. Dearden S, Stevens J, Wu YL, Blowers D. Mutation incidence and coincidence in non small-cell lung cancer: Meta-analyses by ethnicity and histology (mutMap). Ann Oncol. 2013; 24(9):2371-2376. DOI: 10.1093/annonc/mdt205.
4. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018; 378(2):113-125. DOI: 10.1056/NEJMoa1713137.
5. Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023; 389(21):1935-1948. DOI: 10.1056/NEJMoa2306434.
6. Yamamoto G, Asahina H, Honjo O, et al. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: A retrospective multicenter study (HOT2002). Sci Rep. 2021; 11(1):23140. DOI:10.1038/s41598- 021-02561-z.
7. D’Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol Off J Am Soc Clin Oncol. 2011; 29(15):2066-2070. DOI: 10.1200/JCO.2010.32.6181.
8. Chen T, Zhou F, Jiang W, et al. Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients. J Thorac Dis. 2019; 11(6). DOI: 10.21037/jtd.2019.06.24.
9. Lorenzi M, Ferro A, Cecere F, et al. First-line osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: Outcome and safety in the real world: FLOWER study. Oncologist. 2022; 27(2):87-e115. DOI: 10.1002/onco.13951.